Physician profile
Ted P Yang
NPI 1407865959
$15,510.20
in general payments reported to CMS, 2019-2025
37 companies · $2,111 in 2025
The $2,111 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,684 · 2020: $553 · 2021: $2,467 · 2022: $2,068 · 2023: $2,591 · 2024: $2,037 · 2025: $2,111.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,684 · Gift: $42.61 · Education: $12.19.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,684.06 |
| Gift | $42.61 |
| Education | $12.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,419.24 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $1,882.08 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $1,230.90 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $1,213.16 | 2021-2025 | Verquvo, Capvaxive |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $960.79 | 2019-2025 | Lifevest |
| Pfizer INC. | $882.36 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $879.41 | 2019-2025 | Farxiga, Wainua, Brilinta |
| Bayer Healthcare Pharmaceuticals INC. | $777.28 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $760.82 | 2022-2025 | Camzyos, Eliquis |
| Amgen INC. | $597.87 | 2019-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $583.99 | 2019-2025 | Jardiance |
| Shockwave Medical, INC | $400.46 | 2021-2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Novo Nordisk INC | $344.37 | 2021-2025 | Ozempic, Wegovy |
| Amarin Pharma, INC. | $326.52 | 2021-2022 | |
| Alnylam Pharmaceuticals INC. | $286.50 | 2019-2024 | Amvuttra |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ted Yang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.